OBJECTIVE:To observe the efficacy and safety of valsartan combined with prednisone in the treatment of idiopath-ic pulmonary fibrosis. METHODS:50 patients with idiopathic pulmonary fibrosis were randomly divided into control group and ob-servation group. Control group was orally given 0.5 mg/(kg·d)Prednisone acetate tablet in 1-4 weeks,then maintained with 0.125 mg/(kg·d)in 5-12 neeks,2-3 times a day;observation group was additionally given 80 mg Valsartan capsule,orally,once a day. The treatment course for both groups was 6 months. Pulmonary function indicators [forced vital capacity(FVC),peak expiratory flow rate (PEFR),and forced expiratory volume in one second (FEV1)],serum inflammatory factor indicators [interleukin-13(IL-13), IL-18,transforming growth factor-β1(TGF-β1)] level,matrix metalloproteinase-9(MMP-9),MMP-2 contents and the incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,the difference was statistically significant(P0.05);af-ter treatment,pulmonary function indicators in 2 groups were significantly higher than before,and observation group was higher than control group,MMP-9 and MMP-2 contents were significantly lower than before,and observation group was lower than con-trol group(P0.05). CONCLUSIONS:Valsartan combined with prednisone can significantly improve the pulmonary function of patients with idiopathic pulmonary fibrosis,and reduce the contents of serum inflammatory cytokines and matrix metalloproteinases,with good safety.%目的：观察缬沙坦联合泼尼松对特发性肺间质纤维化的疗效和安全性。方法：50例特发性肺间质纤维化患者随机均分为对照组和观察组。对照组患者给予醋酸泼尼松片1～4周0.5 mg/（kg·d），5～12周0.25 mg/（kg·d），后以0.125 mg/（kg·d）维持治疗，每日2～3次；观察组患者在对照组治疗的基础上给予缬沙坦胶囊80 mg，口服，每日1次。两组患者疗程均为6个月。观察两组患者的临床疗效，治疗前后肺功能指标[用力肺活量（FVC）、最大呼气峰流速（PEFR）、第一秒用力呼气容积（FEV1）]、血清炎症因子指标[白细胞介素（IL）-13、IL-18、转化生长因子（TGF）-β1]水平，基质金属蛋白酶（MMP）-9、MMP-2含量及不良反应发生情况。结果：观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。治疗前，两者患者肺功能指标、血清炎症因子指标、MMP-9、MMP-2含量比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者肺功能指标均显著高于同组治疗前，且观察组高于对照组，血清炎症因子水平和MMP-9、MMP-2含量均显著低于同组治疗前，且观察组低于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异均无统计学意义（P＞0.05）。结论：缬沙坦联合泼尼松可显著改善特发性肺间质纤维化患者肺功能，降低血清炎性因子及基质金属蛋白酶的含量，疗效显著，安全性较好。
展开▼
